Show simple item record

dc.creatorBanerjee, Shubhasree
dc.creatorGeorge, Michael
dc.creatorYoung, Kalen
dc.creatorVenkatachalam, Shilpa
dc.creatorGordon, Jennifer
dc.creatorBurroughs, Cristina
dc.creatorCurtis, David
dc.creatorFerrada, Marcela
dc.creatorGavigan, Kelly
dc.creatorGrayson, Peter C.
dc.creatorKullman, Joyce
dc.creatorDanila, Maria I.
dc.creatorCurtis, Jeffrey R.
dc.creatorShaw, Dianne G.
dc.creatorNowell, W. Benjamin
dc.creatorMerkel, Peter A.
dc.identifier.citationBanerjee, S., George, M., Young, K., Venkatachalam, S., Gordon, J., Burroughs, C., Curtis, D., Ferrada, M., Gavigan, K., Grayson, P.C., Kullman, J., Danila, M.I., Curtis, J.R., Shaw, D.G., Benjamin Nowell, W., Merkel, P.A. and (2021), Effects of the COVID‐19 Pandemic on Patients Living With Vasculitis. ACR Open Rheumatology, 3: 17-24.
dc.description.abstractThis study aimed to analyze the concerns and health‐related behaviors in patients with vasculitis during the early phase of the coronavirus disease 2019 (COVID‐19) pandemic in North America. Patients with vasculitis in North America were invited to complete an online survey through the Vasculitis Patient‐Powered Research Network in collaboration with the Vasculitis Foundation and the Relapsing Polychondritis Foundation. Questions focused on concerns and behaviors related to doctors’ visits, tests, medication, and telehealth use. Factors affecting their concern and health‐related behaviors were determined. Data from 662 patients were included: 90% of patients were White, 78% were women, 83% expressed moderate or high levels of concern about COVID‐19, and 87% reported that their vasculitis moderately or extremely affected their level of concern. Older age, female sex, lung disease, and immunosuppression were associated with greater concern. Doctors’ visits, laboratory tests, and other tests were avoided by 66%, 46%, and 40% of patients, respectively. Younger age, urban location, higher income, higher concern levels, and prednisone use (>10 mg/day) were associated with greater likelihood of avoiding visits or tests. Ten percent of patients on immunosuppressive therapy stopped their medication. Twenty‐nine percent patients on rituximab avoided an infusion. Forty‐four percent of patients had telehealth visits; more visits were reported for younger patients, for patients on glucocorticoids, and in Canada versus the United States. During the COVID‐19 pandemic, patients with vasculitis have high levels of concern and exhibit potentially harmful health‐related behaviors. Health care use varies across different demographic groups and geographic regions. Specific strategies are warranted to facilitate engagement of these patients with the health care system during the pandemic.
dc.format.extent8 pages
dc.relation.ispartofCOVID-19 Research
dc.relation.haspartACR Open Rheumatology, Vol. 3, Issue 1
dc.rightsAttribution-NonCommercial CC BY-NC
dc.titleEffects of the COVID‐19 Pandemic on Patients Living With Vasculitis
dc.type.genreJournal article
dc.contributor.groupVasculitis Patient‐Powered Research Network
dc.description.departmentNeuroscience and Neurovirology
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeLewis Katz School of Medicine
dc.temple.creatorGordon, Jennifer

Files in this item

Gordon-JournalArticle-2020-12- ...

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial CC BY-NC
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC